Profile data is unavailable for this security.
About the company
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS is a Turkey-based company, which engages in manufacturing of pharmaceuticals and other health products. The Company operates in the fields of manufacturing all kinds of pharmaceuticals for human use and health products, trading, import and export. Gen Ilac manufactures products used in the treatment of rare diseases and disorders in neurology, endocrinology, nephrology, oncology, hematology and pediatric branches. The Company has approximately 500 employees working in its production facilities on a closed area of 15,000 square meters, established on an area of approximately 43,000 square meters in Ankara ASO 2nd and 3rd Organized Industrial Zone. Entity has 5 offices abroad: Germany, Russia, Kazakhstan, Uzbekistan and Azerbaijan.
- Revenue in TRY (TTM)12.60bn
- Net income in TRY178.31m
- Incorporated1997
- Employees617.00
- LocationGen Ilac ve Saglik Urunleri Sanayi ve Ticaret ASMustafa Kemal Mahallesi 2119.Cad. No:3CankayaANKARA 06520TurkeyTUR
- Phone+90 3 122196219
- Fax+90 3 122196010
- Websitehttps://www.genilac.com.tr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Torii Pharmaceutical Co Ltd | 13.16bn | 1.21bn | 26.12bn | 583.00 | 21.10 | 0.9208 | 19.96 | 1.98 | 186.93 | 186.93 | 2,036.86 | 4,284.47 | 0.4304 | 2.79 | 2.23 | 98,195,540.00 | 3.95 | 6.52 | 4.36 | 7.35 | 44.49 | 49.55 | 9.18 | 17.98 | 5.70 | -- | 0.00 | 24.17 | 11.74 | -2.67 | 4.44 | 28.76 | -20.38 | 20.11 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 7.96bn | 2.49bn | 26.44bn | 1.14k | 10.62 | 0.6176 | 8.46 | 3.32 | 3.63 | 3.63 | 11.61 | 62.47 | 0.2079 | 3.86 | 6.86 | 6,955,255.00 | 6.50 | 8.49 | 7.05 | 9.06 | 33.66 | 32.94 | 31.29 | 58.23 | 0.9382 | -- | 0.0722 | -- | 86.94 | 56.41 | -8.16 | 62.73 | 141.59 | 31.51 |
| Sichuan Huiyu Pharmaceutical Co Ltd | 4.89bn | 661.24m | 26.57bn | 1.36k | 40.19 | 1.47 | -- | 5.43 | 0.3218 | 0.3218 | 2.38 | 8.77 | 0.2222 | 1.06 | 13.03 | 739,518.20 | 2.93 | 10.41 | 3.56 | 12.76 | 83.61 | 89.89 | 13.18 | 21.42 | 2.76 | -- | 0.1296 | 20.54 | -37.92 | 76.37 | -43.86 | -- | 66.72 | -- |
| Gen Ilac ve Saglik Urnlr Snyi ve Tcrt AS | 12.60bn | 178.31m | 26.81bn | 617.00 | 150.32 | 4.55 | 47.28 | 2.13 | 0.5944 | 0.5944 | 42.00 | 19.62 | 1.68 | 15.72 | 9.78 | 20,256,010.00 | 2.31 | 12.39 | 3.73 | 17.53 | 19.31 | 19.06 | 1.37 | 6.95 | 1.29 | 3.41 | 0.1773 | -- | -23.38 | 47.18 | -28.97 | 147.97 | -- | -- |
| Hunan Fangsheng Pharmaceutical Co Ltd | 8.17bn | 1.05bn | 26.86bn | 1.69k | 25.09 | 3.67 | -- | 3.29 | 0.5026 | 0.5026 | 3.87 | 3.44 | 0.5372 | 1.44 | 6.24 | 998,562.10 | 6.67 | 5.39 | 11.80 | 9.37 | 68.22 | 66.91 | 12.43 | 8.95 | 0.472 | 14.06 | 0.3458 | 46.47 | -9.12 | 9.15 | -34.64 | 20.68 | 23.91 | 4.75 |
| Shouyao Holdings Co Ltd | 19.55m | -947.54m | 27.04bn | 185.00 | -- | 6.07 | -- | 1,383.42 | -1.31 | -1.31 | 0.0271 | 6.17 | 0.0036 | 0.2578 | 1.35 | 21,779.19 | -17.49 | -37.24 | -19.17 | -42.63 | 95.40 | 96.03 | -4,847.44 | -2,251.77 | 7.47 | -- | 0.0093 | -- | 186.18 | -23.51 | -6.76 | -- | 34.59 | -- |
| Sun Pharma Advanced Research Co Ltd | 278.84m | -1.58bn | 27.27bn | 409.00 | -- | -- | -- | 97.79 | -11.97 | -11.97 | 2.11 | -- | -- | -- | -- | 1,672,501.00 | -- | -61.70 | -- | -119.31 | 59.81 | 74.49 | -568.24 | -163.40 | -- | -208.33 | -- | -- | -68.36 | -16.21 | -73.96 | -- | 15.40 | -- |
| Guizhou Sanli Pharmaceutical Co Ltd | 9.34bn | 1.50bn | 27.40bn | 2.28k | 18.85 | 3.70 | -- | 2.93 | 0.7311 | 0.7311 | 4.59 | 3.72 | 0.7844 | 2.50 | 4.26 | 843,357.60 | 12.76 | 12.39 | 19.35 | 16.72 | 70.14 | 70.45 | 16.27 | 16.31 | 1.52 | -- | 0.2486 | 25.70 | 36.10 | 17.75 | 45.42 | 21.51 | 127.48 | -- |
| Cronos Group Inc | 3.48bn | -1.96bn | 27.77bn | 626.00 | -- | 0.7644 | -- | 7.97 | -0.2067 | -0.2069 | 0.3666 | 3.81 | 0.0901 | 2.29 | 7.09 | -- | -5.13 | 6.43 | -5.26 | 7.11 | 16.37 | -10.54 | -56.97 | 147.07 | 27.41 | -- | 0.00 | -- | 0.5672 | 48.40 | 54.99 | -- | -50.99 | -- |
Data as of Oct 11 2024. Currency figures normalised to Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's reporting currency: Turkish Lira TRY
4.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 7.96m | 2.65% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.84m | 0.95% |
| HSBC Portf�y Y�netim ASas of 30 Jun 2024 | 700.00k | 0.23% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 245.22k | 0.08% |
| State Street Global Advisors Ltd.as of 04 Jul 2024 | 174.53k | 0.06% |
| Charles Schwab Investment Management, Inc.as of 03 Jul 2024 | 139.95k | 0.05% |
| HSBC Asset Management (India) Pvt Ltd.as of 30 Apr 2024 | 130.00k | 0.04% |
| Mellon Investments Corp.as of 03 Jul 2024 | 116.67k | 0.04% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 73.72k | 0.03% |
| Parametric Portfolio Associates LLCas of 30 Jun 2024 | 61.79k | 0.02% |
More ▼
Data from 31 Dec 2023 - 08 Aug 2024Source: FactSet Research Systems Inc.
